NASDAQ:PTGX

Protagonist Therapeutics (PTGX) Stock Forecast, Price & News

$26.07

+0.60 (+2.36%)

(As of 05/31/2023 ET)

Compare

Today's Range: $25.07
▼
$26.14
50-Day Range: $18.02
▼
$26.33
52-Week Range: $6.91
▼
$27.10

Volume: 975,279 shs
Average Volume: 892,213 shs
Market Capitalization: $1.49 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.67

Protagonist Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 36.8% Upside
$35.67 Price Target
Short Interest: Healthy
6.29% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.03
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.34) to ($2.21) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

364th out of 1,006 stocks

Pharmaceutical Preparations Industry

166th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.67, Protagonist Therapeutics has a forecasted upside of 36.8% from its current price of $26.07.
Amount of Analyst Coverage
Protagonist Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.29% of the outstanding shares of Protagonist Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Protagonist Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Protagonist Therapeutics has recently decreased by 3.23%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Protagonist Therapeutics does not currently pay a dividend.
Dividend Growth
Protagonist Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PTGX.

3.4

News and Social Media Coverage

News Sentiment
Protagonist Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Protagonist Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Protagonist Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Protagonist Therapeutics is held by insiders.
Percentage Held by Institutions
91.51% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Protagonist Therapeutics are expected to grow in the coming year, from ($2.34) to ($2.21) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Protagonist Therapeutics is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Protagonist Therapeutics is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Protagonist Therapeutics has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Stock News Headlines

May 26, 2023 | finance.yahoo.com

How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%

May 26, 2023 | msn.com

Here's What Could Help Protagonist Therapeutics (PTGX) Maintain Its Recent Price Strength

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 25, 2023 | seekingalpha.com

Protagonist Therapeutics Sees Steady If Bumpy Progress

May 22, 2023 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Research Coverage Started at StockNews.com

May 12, 2023 | finance.yahoo.com

Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment

May 12, 2023 | finance.yahoo.com

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

May 11, 2023 | finance.yahoo.com

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference

June 1, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

May 11, 2023 | finance.yahoo.com

Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association

May 10, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for Protagonist Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:PTGX)

May 5, 2023 | msn.com

Unusual Put Option Trade in Protagonist Therapeutics (PTGX) Worth $476.38K

May 4, 2023 | msn.com

Protagonist Therapeutics: Q1 Earnings Insights

April 28, 2023 | msn.com

HC Wainwright & Co. Reiterates Protagonist Therapeutics (PTGX) Buy Recommendation

April 27, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Protagonist Therapeutics

April 18, 2023 | markets.businessinsider.com

Protagonist Therapeutics (PTGX) Receives a Buy from JMP Securities

April 17, 2023 | finance.yahoo.com

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Yet to Catch Up With Its Share Price

April 14, 2023 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Trading 4.3% Higher

April 8, 2023 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Trading 3.9% Higher

April 7, 2023 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Down to $21.55

April 6, 2023 | markets.businessinsider.com

Protagonist Therapeutics Declines 8% After Pricing 5 Mln Share Offering

April 5, 2023 | markets.businessinsider.com

Why Protagonist Therapeutics Shares Are Nosediving

April 5, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock

April 5, 2023 | msn.com

Protagonist Therapeutics prices $100M offering

April 5, 2023 | finance.yahoo.com

Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock

April 4, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

April 4, 2023 | finance.yahoo.com

Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Company Calendar

Last Earnings: 3/15/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PTGX
CUSIP: N/A
CIK: 1377121
Web: www.protagonist-inc.com
Phone: (510) 474-0170
Fax: N/A
Employees: 118
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $35.67
High Stock Price Forecast: $41.00
Low Stock Price Forecast: $28.00
Forecasted Upside/Downside: +36.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-127,390,000.00
Net Margins: N/A
Pretax Margin: -16,319.91%
Return on Equity: -59.44%
Return on Assets: -51.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.15
Quick Ratio: 10.15

Sales & Book Value

Annual Sales: $26.58 million
Price / Sales: 56.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.78 per share
Price / Book: 6.90

Miscellaneous

Outstanding Shares: 57,250,000
Free Float: 54,388,000
Market Cap: $1.49 billion
Optionable: Not Optionable
Beta: 1.96

Key Executives

Dinesh V. Patel
President, Chief Executive Officer & Director

Asif Ali
Chief Financial Officer & Executive Vice President

Mohammad Masjedizadeh
Chief Technical Officer & Executive VP

Arturo Molina
Chief Medical Officer

Matthew M. Gosling
Executive Vice President & General Counsel

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PTGX Stock - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings or view top-rated stocks.
What is Protagonist Therapeutics' stock price forecast for 2023?: 2 Wall Street research analysts have issued 12-month price objectives for Protagonist Therapeutics' stock. Their PTGX share price forecasts range from $28.00 to $41.00. On average, they expect the company's stock price to reach $35.67 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.
How have PTGX shares performed in 2023?: Protagonist Therapeutics' stock was trading at $10.91 at the beginning of 2023. Since then, PTGX shares have increased by 139.0% and is now trading at $26.07.
View the best growth stocks for 2023 here.
When is Protagonist Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PTGX earnings forecast.
How were Protagonist Therapeutics' earnings last quarter?: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.02.
What ETFs hold Protagonist Therapeutics' stock?: ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include Innovator IBD Breakout Opportunities ETF (BOUT), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA Healthcare Momentum ETF (PTH), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), BlackRock Future Health ETF (BMED) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).
What other stocks do shareholders of Protagonist Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?: (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.
What is Protagonist Therapeutics' stock symbol?: Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."
Who are Protagonist Therapeutics' major shareholders?: Protagonist Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.04%), BlackRock Inc. (7.69%), BVF Inc. IL (6.60%), Farallon Capital Management LLC (4.57%), State Street Corp (4.22%) and Dimensional Fund Advisors LP (2.20%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends.
How do I buy shares of Protagonist Therapeutics?: Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Protagonist Therapeutics' stock price today?: One share of PTGX stock can currently be purchased for approximately $26.07.
How much money does Protagonist Therapeutics make?: Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $1.49 billion and generates $26.58 million in revenue each year. The company earns $-127,390,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.
How many employees does Protagonist Therapeutics have?: The company employs 118 workers across the globe.
How can I contact Protagonist Therapeutics?: Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.

This page (NASDAQ:PTGX) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial